Erasca to Present at the Bank of America Securities 2022 Healthcare Conference

About this update from Erasca, Inc.

[{"type":"text","content":"SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2022 Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat at 1:20 p.m. Pacific Time on Tuesday, May 10, 2022, in Las Vegas, Nevada. Drs. Lim and Chacko will also participate in one-on-one investor meetings. A live webcast of the event will be available online at bofa/webcasts/. An archived replay of the event will be available until August 10, 2022, following the webcast at Erasca.com/events. About ErascaAt Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer. Contact:Joyce AllaireLifeSci Advisors, [email protected] Source: Erasca, Inc. \nSource: Erasca, Inc.","length":3699,"tagName":"div"}]

More updates from Erasca, Inc.